Delivery Order SPE2DB22D3501-SPE2DB26FTJ71
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 28, 2025, by the Defense Logistics Agency to supply 60 tablets of Tibsovo 250 mg, a prescription medication used in oncology treatment. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $43,654.80 and is scheduled for completion by October 20, 2025. The contract contains no set-aside designation and...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The $19,882.84 firm fixed price delivery order is for the supply of TIBSOVO 250 MG tablets. The contract has an ultimate completion date of May 14, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of TIBSOVO 250 mg, a pharmaceutical product used in oncology treatment. This firm fixed-price delivery order, valued at $21,827.40, was competitively awarded without set-aside provisions and is scheduled for completion by May 14, 2025. The order was placed on April 23, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $21,827.40 firm fixed-price delivery order is for the supply of TIBSOVO 250 MG tablets. The contract has an ultimate completion date of April 7, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $3,563.78 delivery order from the Defense Logistics Agency (DLA) on April 22, 2025, for ONIVYDE 43 mg/10 mL vials. This firm fixed-price contract, with an ultimate completion date of May 13, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- AmerisourceBergen Drug Corp was awarded a delivery order contract on September 22, 2025, by the Defense Logistics Agency Medical Supply Chain to supply one vial of Trodelvy 180mg, a oncology therapeutic medication, for delivery to Conshohocken, Pennsylvania. The contract is a firm fixed price delivery order with a ceiling value of $19,169.16 and an ultimate completion date of September 23, 2025. No set-aside designation was applied to this competitive award, demonstrating AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,938.00 by the Defense Logistics Agency (DLA) on October 27, 2025, with an ultimate completion date of October 28, 2025. The delivery order is for AmBisome 50 mg vials, a specialty pharmaceutical product. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $24,403.80 by the Defense Logistics Agency on October 28, 2025, for the supply of Ayvakit 200 mg tablets (30-count). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 19, 2025. The contract is a child award issued under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $3,784.00, with completion targeted for September 18, 2025. This is a competitively awarded, non-set-aside delivery order issued by the federal government's medical procurement division. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $50,797.65 delivery order by the Defense Logistics Agency on May 12, 2025, for the supply of IMBRUVICA 420 mg tablets (28-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of June 3, 2025. The award represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB26FTJ71Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency (DLA) on November 4, 2025, for TIBSOVO 250 mg tablets (60-count supply) with a firm fixed price ceiling value of $21,827.41. The contract is scheduled for completion by November 26, 2025. This is a competitively awarded, non-set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of medications and medical supplies to support military healthcare systems globally. TIBSOVO (ivosidenib), an oncology medication used in cancer treatment, represents part of AmerisourceBergen's ongoing role as a critical pharmaceutical supplier to the federal government's military and veteran healthcare networks. The delivery order demonstrates the company's continued utilization of its DLA prime vendor contract vehicle to fulfill specific pharmaceutical requirements across the Defense Health Agency and other federal healthcare entities. AmerisourceBergen's performance under similar contracts, which have involved specialty medications, brand-name and generic drugs, and specialized medical supplies across multiple therapeutic domains, positions the company as a key provider within the federal pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.8k | 11/4/25 |